RION spun out Rion Vet, a veterinary biotech venture with exclusive global rights to its Purified Exosome Product (PEP™) platform for animal health applications.
Appointed industry veteran Mark Herthel, co-founder/former CEO of Zoetis-acquired Platinum Performance, as Rion Vet CEO.
Closed a $15 million Series A financing led by Herthel to fund development of exosome-based biologics.
Lead candidate ePEP-01 targets equine musculoskeletal disease; pipeline includes canine musculoskeletal, dermatitis, wound healing, ocular, respiratory, and cardiac programs addressing an estimated $8–12 billion market.

Nov 11, 2025, 2:00 PM

Press Release

Phibro Animal Health reports Q1 FY2026 results

ZTS

Earnings

Guidance Update

Product Launch

Net sales of $363.9 million for Q1 ended September 30, 2025, a 40% increase year-over-year.
Net income of $26.5 million and diluted EPS of $0.65, up $19.6 million and $0.48, respectively, versus prior year.
Adjusted EBITDA of $61.9 million, an increase of $31.2 million compared to Q1 FY2025.
Raised full-year FY2026 adjusted EBITDA guidance to $230 million–$240 million and maintained net sales guidance of $1.43 billion–$1.48 billion.
National launch of Restoris™ dental gel for dogs with periodontal disease to expand companion animal oral health portfolio.

Nov 5, 2025, 9:22 PM

Press Release

Zoetis publishes brain AI-assisted diagnosis market forecast to 2029

ZTS

Market grew from $1.74 billion in 2024 to $2.19 billion in 2025 (CAGR 25.9%) and is projected to reach $5.46 billion by 2029 (CAGR 25.6%).
Key growth drivers include rising neurological disorder prevalence, healthcare digitization initiatives, preventive healthcare adoption, aging populations, and demand for early disease detection.
Emerging trends feature advanced neuroimaging, personalized diagnostic platforms, hybrid therapeutic-diagnostic solutions, big data analytics integration, and VR-based cognitive assessments.
Competitive landscape is led by North America (2024), with major players like Viz.ai, Aidoc Medical, RapidAI, Qure.ai, Ceribell, BrainScope, and others; notable M&A includes SyntheticMR AB’s $5.03 million acquisition of Combinostics Oy in January 2025.

Nov 4, 2025, 3:47 PM

Press Release

Zoetis reports Q3 2025 earnings

ZTS

Earnings

Guidance Update

Management Change

Zoetis posted $2.4 billion in Q3 revenue, up 1% on a reported basis and 4% on an organic operational basis; adjusted net income was $754 million, up 5% reported and 9% organic.
By segment, global companion animal revenue totaled $1.7 billion (up 2% organic), with the Simparica franchise at $356 million (+ 7%), key dermatology at $469 million (+ 3%) and OA pain at $138 million (– 11%); livestock revenue was $725 million, up 10% organic.
Full-year guidance was narrowed: revenue of $9.4 billion–$9.475 billion (organic growth 5.5%–6.5%), adjusted net income of $2.8 billion–$2.84 billion (organic growth 5.5%–7%), and EPS maintained at $5.90–$6.00 reported and $6.30–$6.40 adjusted.
Leadership update: R&D head Rob Polzer will retire end-February 2026, with Kevin Esch succeeding effective January 1, 2026.

Nov 4, 2025, 1:30 PM

Transcript

Zoetis reports Q3 2025 results

ZTS

Earnings

Guidance Update

Zoetis posted $2.4 billion in Q3 revenue (+1% reported, +4% organic operational) and $754 million in adjusted net income (+5% reported, +9% organic operational).
Companion Animal revenues were $1.7 billion, up 2% operationally; key franchises: Simparica $356 million (+7%), dermatology $469 million (+3%), while OA pain declined 11% to $138 million; livestock reached $725 million, up 10% organically.
International revenue grew 6% organically: Simparica international $93 million (+22%), dermatology $162 million (+7%); OA pain international fell 3% to $80 million, and livestock grew 8%.
Full-year 2025 guidance narrowed: organic operational revenue growth to 5.5–6.5%, organic operational adjusted net income growth to 5.5–7%, with revenue now expected at $9.40–$9.475 billion and adjusted net income at $2.80–$2.84 billion.

Nov 4, 2025, 1:30 PM

Transcript

Zoetis reports Q3 2025 results

ZTS

Earnings

Guidance Update

Zoetis reported $2.4 billion in Q3 revenue (+1% reported; +4% organic operational) and $754 million in adjusted net income (+5% reported; +9% organic operational).
Companion animal revenue reached $1.7 billion (+2% operationally), driven by parasiticide growth to $356 million (+7%) and dermatology to $469 million (+3%), offset by an 11% decline in OA pain to $138 million; livestock revenue grew 10% organically to $725 million.
Adjusted gross margin expanded by 90 bps to 71.6%, and adjusted diluted EPS rose 7% operationally; foreign exchange added 20 bps to margins.
Maintained 2025 full-year EPS guidance of $5.90–$6.00 reported and $6.30–$6.40 adjusted, while adjusting revenue guidance to $9.4–$9.475 billion (organic growth 5.5%–6.5%) and net income guidance to $2.8–$2.84 billion.

Nov 4, 2025, 1:30 PM

Transcript

Zoetis reports Q3 2025 earnings

ZTS

Earnings

Guidance Update

Product Launch

Reported 4% revenue growth and 9% organic operational growth in adjusted net income (adjusted diluted EPS up 7% operationally, 12% organically).
Parasiticides franchise grew 7% (Simparica Trio up 6%), dermatology up 3%, while OA pain declined 11% (Librela down 15%).
Livestock segment delivered 10% organic operational growth globally (and 8% internationally) on broad‐based strength across species.
Secured approvals for Linivi in Canada and positive EU opinion, plus EU approval for Portela; Solensia cat OA grew 9% to $18 M internationally; new long‐acting OA launches expected H1 2026.
Raised full‐year 2025 guidance to $9.4–9.475 B revenue (organic growth 5.5–6.5%), adjusted net income $2.8–2.84 B, while maintaining adjusted diluted EPS at $6.30–6.40.

Nov 4, 2025, 1:30 PM

Transcript

Zoetis announces Q3 2025 results

ZTS

Earnings

Guidance Update

Reported revenue of $2.4 billion in Q3, up 1% YoY, but down 4% on an organic operational basis (4% price, 0% volume).
Adjusted net income of $754 million and adjusted diluted EPS of $1.70, up 5% and 8% reported YoY, yet down 9% and 12% on an organic operational basis, respectively.
U.S. segment revenue grew 3% organically to $1.3 billion, while International segment revenue rose 6% organically to $1.1 billion.
Key portfolio drivers included 10% organic growth in livestock revenue and 7% growth in the Simparica franchise in Q3.
Full-year 2025 revenue guidance narrowed to $9.40–$9.475 billion with 5.5%–6.5% organic operational growth; adjusted EPS guidance maintained at $6.30–$6.40.

Nov 4, 2025, 1:30 PM

Presentation

Zoetis announces Q3 2025 results

ZTS

Earnings

Guidance Update

Zoetis reported Q3 revenue of $2.4 billion, up 1% y-o-y, with 4% organic operational growth.
Net income was $721 million ($1.63 per diluted share), up 6% y-o-y; adjusted net income was $754 million ($1.70 per diluted share), up 5% y-o-y.
U.S. segment revenue was $1.3 billion (–2% reported, +3% organic), while International revenue was $1.1 billion (+3% reported, +6% organic).
Full year 2025 guidance revised to $9.400–$9.475 billion in revenue (5.5–6.5% organic growth), narrows adjusted net income growth to 5.5–7.0%, and maintains adjusted EPS at $6.30–$6.40.

Nov 4, 2025, 12:06 PM

8-K

Zoetis reports Q3 2025 results

ZTS

Earnings

Guidance Update

Zoetis reported Q3 2025 revenue of $2.4 B, up 1% YoY, with 4% organic operational growth.
Net income was $721 M, or $1.63 diluted EPS (up 6% and 9%, respectively), and adjusted net income was $754 M, or $1.70 EPS (+5% and 8% reported; +9% and 12% organically).
U.S. segment revenue: $1.3 B (–2% reported; +3% organic); International segment revenue: $1.1 B (+3% reported; +6% organic).
Revised full-year 2025 guidance to $9.400–$9.475 B in revenue (organic growth 5.5%–6.5%), narrowed adjusted net income growth to 5.5%–7.0%, and maintained adjusted EPS at $6.30–$6.40.

Nov 4, 2025, 12:00 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for ZTS.

No recent filings or transcripts found for ZTS.